To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castration-resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The Georgetown University Lombardi Comprehensive Cancer Center held a lecture on how certain white blood cells in the immune system can contribute to bone metastatic prostate cancer as part of their ...

Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a ...

metastatic prostate cancer. The other goal of the study is to find the maximum tolerated dose of the therapy. MORE: CT scans cause more cancer cases than previously believed, study shows "If this ...

delivering radiation directly to prostate cancer cells while sparing healthy tissue. Patients receiving Lu-177-PSMA therapy often show significant reductions in PSA levels, tumor burden, and bone ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer ... even before symptoms begin.

The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves a combination of therapies, including ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment ... the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with zoledronic ...

Intravenous; mCRPC: Metastatic ... event in bone metastatic patients who are unfit for or pretreated with docetaxel. The identification of new drug resistance mechanisms and prostate cancer ...